pentobarbital will reduce the level or impact of cannabidiol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Think about a rise in cannabidiol dosage (based on medical reaction and tolerability) when coadministered with a strong CYP3A4 inducer.
pentobarbital will increase toxicity of buprenorphine, prolonged-performing injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants boosts possibility of adverse reactions together with overdose, respiratory depression, and Loss of life. Cessation of benzodiazepines or other CNS depressants is favored most often.
pentobarbital will reduce the level or effect of fostemsavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
benzhydrocodone/acetaminophen and pentobarbital both equally improve sedation. Prevent or Use Alternate Drug. Limit use to clients for whom substitute procedure selections are insufficient
Reserve concomitant prescribing of these drugs in patients for whom other treatment method choices are insufficient. Limit dosages and durations on the bare minimum expected. Observe carefully for indications check here of respiratory depression and sedation.
pentobarbital will decrease the extent or effect of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Closely. Advised atogepant dosage with concomitant utilization of sturdy or moderate CYP3A4 inducers is thirty mg or 60 mg qDay.
pentobarbital will lower the level or outcome of cevimeline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unidentified.
pentobarbital will lessen the level or influence of diazepam buccal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Potent or reasonable CYP3A4 inducers may raise charge of diazepam elimination; as a result, efficacy of diazepam might be lowered.
pentobarbital will decrease the extent or result of levoketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unknown.
Coadministration of zuranolone with other CNS depressants may possibly boost impairment of psychomotor functionality or CNS depressant effects. If unavoidable, take into consideration dose reduction. .
pentobarbital will decrease the level or effect of armodafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.
pentobarbital will lessen the extent or impact of sufentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.
pentobarbital will lessen the level or result of diazepam intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Potent or average CYP3A4 inducers may possibly enhance amount of diazepam elimination; thus, efficacy of diazepam may very well be lessened.
pentobarbital will decrease the extent or outcome of quinidine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.